NCT00243477

MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting

MOTIV Study. Effect of Antidepressive Treatment by Escitalopram Started Preoperatively in Patients Undergoing Coronary Artery Bypass Grafting

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 368 (actual)
• Sponsor: Hopital Jean Minjoz · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effect of an antidepressive medication (Escitalopram), started preoperatively and given during 6 months, on 6-month and 1 year post-operative morbidity and mortality after coronary artery bypass grafting

Detailed description

Depression is known to have an adverse effect on post-operative mortality and morbidity after coronary artery bypass grafting. Cardiac surgery is known to cause transient depression in patients. The purpose of this double-blind, randomized study is to determine the effect of an antidepressive medication (Escitalopram), started preoperatively and given during 6 months, on 6-month and 1 year post-operative morbidity and mortality after coronary artery bypass grafting. Treatment is given from 21 to 15 days pre-operatively until the 6th post-operative month. Morbidity as defined by the STS database as well as mortality is checked during 1 year.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Escitalopram	Escitalopram 10mg or placebo once a day

Timeline

• Start date: 2006-01-01
• Primary completion: 2011-02-01
• Completion: 2012-02-01
• First posted: 2005-10-24
• Last updated: 2012-03-19

Locations

1 site across 1 country: France